🇺🇸 FDA
Pipeline program

Dose A KER-012

KER-012-A201

Phase 2 mab completed

Quick answer

Dose A KER-012 for Pulmonary Arterial Hypertension is a Phase 2 program (mab) at Keros Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Keros Therapeutics
Indication
Pulmonary Arterial Hypertension
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials